Clinical Trials Logo

Gastric Cancer in Situ clinical trials

View clinical trials related to Gastric Cancer in Situ.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03162510 Completed - Clinical trials for Gastric Cancer in Situ

Biweekly SOLAR, as First-line C/T in Pts With Gastric, Pancreatic and Biliary Cancers

SOLAR
Start date: June 26, 2018
Phase: Phase 1
Study type: Interventional

The primary purpose of the study is to determine the maximal tolerated dose (MTD) of Oxaliplatin in this phase I study. The secondary objectives are to determine the response rate, progression free survival, overall survival, and safety profiles. Eligible patients will receive a triplet chemotherapy consisting of nab-paclitaxel (Abraxane®) 150 mg/m2 IVD 30 min followed by Oxaliplatin 60 - 85 mg/m2 IVD 2hr at D1, plus oral S-1 35mg/m2 and Leucovorin 30mg twice daily from D1 to D7, every 14 days as a cycle till disease progression.